Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Coronary Syndrome
100%
Residual Cardiovascular Risk
100%
Alirocumab
100%
Apolipoprotein B (apo B)
100%
Low-density Lipoprotein Cholesterol (LDL-C)
21%
Placebo Groups
14%
Propensity Score Matching
14%
Non-high-density Lipoprotein Cholesterol (non-HDL-C)
14%
Residual Risk
14%
Atherogenic Lipoproteins
14%
Hazard Ratio
7%
Ischemic Stroke
7%
Low Risk
7%
Placebo
7%
Hospitalization
7%
Nonfatal Myocardial Infarction
7%
Lipoproteins
7%
Cardiovascular Outcomes
7%
Non-fatal
7%
Stable Angina
7%
Statin Therapy
7%
Coronary Heart Disease Mortality
7%
Major Adverse Cardiovascular Events
7%
Group Treatment
7%
Relative Reduction
7%
Cox Proportional Hazards
7%
Incremental Information
7%
Unique Identifier
7%
Predictive Information
7%
Atherogenic Risk
7%
Odyssey
7%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
7%
Hazard Score
7%
Trial Evaluation
7%
During Treatment
7%
Integrated Measure
7%
Proportional Hazard Analysis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Cardiovascular Risk
100%
Apolipoprotein B
100%
Alirocumab
100%
Low Density Lipoprotein Cholesterol
21%
Placebo
21%
Lipoprotein
21%
High Density Lipoprotein Cholesterol
14%
Heart Infarction
7%
Brain Ischemia
7%
Ischemic Heart Disease
7%
Unstable Angina Pectoris
7%
Statin (Protein)
7%
Proprotein Convertase 9
7%
9 [(4 Acetyl 3 Hydroxy 2 Propylphenoxy)methyl] 3 (1h Tetrazol 5 Yl) 4h pyrido[1,2 A]pyrimidin 4 One
7%
Cardiovascular Disease
7%